Metraipolis › archive › dc_d07adf9fb281

Recharacterization of EmAGA, a Potential Candidate for Novel ALL Therapeutics — Europe PMC PMID:42194039

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42194039
DOI
10.3390/biom16050690
License (as archived)
solo-consultazione
Archived
2026-11-02T15:56:39.885Z
SHA-256 of the archived text
f672156d784d11d24a803ffbdc5914a9e623a4c6dfe795e54bd84ed787d587a3
Stable URL of this page
https://metraipolis.com/documento/dc_d07adf9fb281

How to cite

Recharacterization of EmAGA, a Potential Candidate for Novel ALL Therapeutics — Europe PMC PMID:42194039 — Europe PMC (en), https://europepmc.org/article/MED/42194039 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d07adf9fb281 (Metraipolis archive dc_d07adf9fb281, sha256 f672156d784d11d24a803ffbdc5914a9e623a4c6dfe795e54bd84ed787d587a3)
BibTeX
@misc{dcd07adf9fb281,
  title = {Recharacterization of EmAGA, a Potential Candidate for Novel ALL Therapeutics — Europe PMC PMID:42194039},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42194039},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d07adf9fb281; sha256 f672156d784d11d24a803ffbdc5914a9e623a4c6dfe795e54bd84ed787d587a3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42194039. Agents can read the archived copy with the MCP tool read_document.